Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

Telescope Innovations Provides Financial Results of Second Fiscal Quarter 2026

TELI · Price

Executive Summary

  • Telescope Innovations reported Q2 FY2026 revenues of $1.64 million, contributing to a year-to-date gross revenue increase to $4.3 million compared to $2.2 million in the previous year.
  • The company achieved significant operational milestones, including the delivery of a second Self-Driving Laboratory (SDL) to Pfizer and the successful production of battery-grade lithium carbonate via its ReCRFT™ process.
  • Despite revenue growth, the company saw an increase in expenses due to aggressive hiring and product fulfillment costs, resulting in an adjusted EBITA loss of $0.71 million for the quarter.

Key Details

Financial Performance (Q2 FY2026) * Revenues: $1.64 million CAD (compared to $1.00 million in Q2 FY2025). * Expenses: $3.11 million CAD (compared to $1.72 million in Q2 FY2025). * Adjusted EBITA Loss: $0.71 million CAD (compared to a loss of $0.44 million in Q2 FY2025). * Year-to-Date Gross Revenues: $4.3 million CAD (compared to $2.2 million for the same six-month period last year). * Expense Drivers: Increased costs associated with hiring technical, sales, and research staff; parts and travel expenses related to product sales, installation, training, and general sales activity.

Self-Driving Labs (SDL) * Delivered a second SDL unit to Pfizer. * Conducted an SDL inauguration at the Korean Pharmaceutical and Biopharma Manufacturer's Association, supported by Dr. Barry Sharpless, the Acceleration Consortium, and Global Affairs Canada.

Lithium Processing Portfolio * Infrastructure: Secured additional laboratory space adjacent to primary labs at the University of British Columbia for ReCRFT™ (lithium carbonate) and DualPure™ (lithium sulfide) development. * ReCRFT™ Process: Produced battery-grade lithium carbonate from battery recycling streams; a collaboration partner successfully integrated this material into a functional battery cell. * DualPure™ Program: Continuing advancement in partnership with Standard Lithium Ltd.; currently engaged in advanced technical discussions with solid-state battery industry leaders in Asia and North America.

Notable Quotes

  • Henry Dubina, CEO: "Delivering our second Self-Driving Laboratory to Pfizer, expanding internationally, demonstrating lithium battery recycling through our ReCRFT™ process, and expanding our lab infrastructure to grow the lithium portfolio all demonstrate technical proof and strong market demand across our platforms."
Read the original news release →

More from Telescope Innovations Corp.